Haematologic malignancies
4 trials- 2019MAIATransplant-ineligible NDMMIn 737 patients with newly diagnosed transplant-ineligible multiple myeloma, daratumumab + lenalidomide + dexamethasone improved progression-free and overall survival compared with lenalidomide + dexamethasone.
- 2018MURANORelapsed/refractory CLLIn 389 patients with relapsed or refractory chronic lymphocytic leukaemia, fixed-duration venetoclax + rituximab for two years improved progression-free survival compared with bendamustine + rituximab.
- 2017ZUMA-1Refractory DLBCLIn 101 patients with refractory aggressive large B-cell lymphoma, axicabtagene ciloleucel (anti-CD19 CAR-T) produced durable complete remissions in a setting with no effective standard therapy.
- 2003IRISChronic myeloid leukaemiaIn 1,106 patients with newly diagnosed chronic-phase CML, imatinib improved cytogenetic response and progression-free survival compared with interferon-α + cytarabine.